Hospital Pharmacy - May 2017 - 346

346

10.

11.

12.

13.

14.

15.

16.
17.

18.

19.

20.

Hospital Pharmacy 52(5)
bevacizumab or single-agent bevacizumab as maintenance
therapy in patients with metastatic colorectal cancer: the phase
III MACRO TTD study. Oncologist. 2012;17(1):15-25.
Jackson CG, Sharples K, Thompson PI, et al. Dose-intense
capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multicentre phase II study. BMC Cancer. 2014;14:737.
Vamvakas L, Matikas A, Karampezis A, et al. Capecitabine in
combination with oxaliplatin and bevacizumab (AXELOX) as
1st line treatment for fit and vulnerable elderly patients (aged
>70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group
(HORG). BMC Cancer. 2014;14:277.
Wong NS, Fernando NH, Bendell JC, et al. A phase II study
of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin
Colorectal Cancer. 2011;10(3):210-216.
Snoeren N, Voest EE, Bergman AM, et al. A randomized two
arm phase III study in patients post radical resection of liver
metastases of colorectal cancer to investigate bevacizumab in
combination with capecitabine plus oxaliplatin (CapOx) vs
CapOx alone as adjuvant treatment. BMC Cancer. 2010;10:545.
Gulhati P, Raghav K, Shroff RT, et al. Bevacizumab combined with capecitabine and oxaliplatin in patients with
advanced adenocarcinoma of the small bowel or ampulla of
Vater: a single-center, open-label, phase 2 study. Cancer.
2016;123(6):1011-1017.
doi:10.1002/cncr.30445.
http://
onlinelibrary.wiley.com/doi/10.1002/cncr.30445/pdf.
Accessed June 7, 2017.
National Cancer Comprehensive Network. NCCN clinical
practice guidelines-colon cancer. Version 2.2017. http://
www.nccn.org. Accessed February 2017.
National Cancer Comprehensive Network. NCCN clinical
practice guidelines-rectal cancer. Version 2.2017. http://
www.nccn.org. Accessed February 2017.
Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin
Oncol. 1997;15(1):103-109.
National Comprehensive Cancer Network. NCCN clinical
practice guidelines-antiemesis. V.2.2016. http://www.nccn.
org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed
February 2017.
Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American
Society of Clinical Oncology focused guideline update. J Clin
Oncol. 2016;34(4):381-386.
Multinational Association for Supportive Care in Cancer.
Antiemetic guidelines. 2016. Version.1.2. Accessed February 2017.
Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation
of clinical evidence and drug cost implications. J Clin Oncol.
2005;23(6):1289-1294.
Terrey JP, Aapro MS. The activity of granisetron in patients
who had previously failed ondansetron antiemetic therapy. Eur
J Clin Res. 1996;8:281-288.
Carmichael J, Keizer HJ, Cupissol D, et al. Use of granisetron
in patients refractory to previous treatment with antiemetics.
Anticancer Drugs. 1998;9(5):381-385.
de Wit R, de Boer AC, vd Linden GH, et al. Effective crossover to granisetron after failure to ondansetron, a randomized

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001;85(8):1099-1101.
Smith IE. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy.
The Granisetron Study Group. J Cancer Res Clin Oncol.
1993;119(6):350-354.
Soukop M. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron
Study Group. Support Care Cancer. 1994;2(3):177-183.
Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer. 2003;89(3):
477-481.
Dold F, Hoey D, Carbery M, et al. Hypersensitivity in patients
with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin. Proc Am Soc Clin Oncol. 2002;21:1478.
Qureshi KM, Leichman C, Berdzik J et al. Incidence of hypersensitivity reactions to oxaliplatin (OXP) at Roswell Park
Cancer Institute (RPCI) and protocol for desensitization. Proc
Am Soc Clin Oncol. 2003;22:789.
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update
of recommendations for the use of white blood cell growth
factors: an evidence-based clinical practice guideline. J Clin
Oncol. 2006;24(19):3187-3205.
National Comprehensive Cancer Network (NCCN). Clinical
practice guidelines in oncology-myeloid growth factors.
Version.2.2013. http://www.nccn.org/professionals/physician_
gls/pdf/myeloid_growth.pdf. Accessed February 2017.
Maroun JA, Anthony LB, Blais N, et al. Prevention and management of chemotherapy-induced diarrhea in patients with
colorectal cancer: a consensus statement by the Canadian
Working Group on chemotherapy-induced diarrhea. Curr
Oncol. 2007;14(1):13-20.
Benson AB, Ajani JA, Catalano RB, et al. Recommended
guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918-2926.
Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and
molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol.
2002;29(suppl 15):21-33.
Otsuji T, Matsuoka M, Saraya Y, et al. Efficacy of calcium
and magnesium infusions for oxaliplatin-related neurotoxicity [abstract 393]. Proc Am Soc Clin Oncol. 2007. http://www.
asco.org/ASCOv2/Meetings/Abstracts?&;vmview=abst_
detail_view&confID=45&abstractID=10308.
Accessed
February 2017.
Grothey G, Nikcevich DA, Sloan JA, et al. Evaluation of the
effect of intravenous calcium and magnesium (CaMg) on
chronic and acute neurotoxicity associated with oxaliplatin:
results from a placebo-controlled phase III trial [abstract 4025].
Proc Am Soc Clin Oncol. 2009. http://www.asco.org/ASCOv2/
Meetings/Abstracts?&vmview=abst_detail_view&confID=65
&abstractID=33721. Accessed February 2017.
Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin
Oncol. 2011;29(4):421-427.
Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced

http://onlinelibrary.wiley.com/doi/10.1002/cncr.30445/pdf http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf http://onlinelibrary.wiley.com/doi/10.1002/cncr.30445/pdf http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf http://www.nccn.org http://www.nccn.org http://www.nccn.org http://www.nccn.org http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf http://www.asco.org/ASCOv2/Meetings/Abstracts?&;vmview=abst_detail_view&confID=45&abstractID=10308 http://www.asco.org/ASCOv2/Meetings/Abstracts?&;vmview=abst_detail_view&confID=45&abstractID=10308 http://www.asco.org/ASCOv2/Meetings/Abstracts?&;vmview=abst_detail_view&confID=45&abstractID=10308 http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33721 http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33721 http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33721

Table of Contents for the Digital Edition of Hospital Pharmacy - May 2017